jnj-40346527
Small moleculeexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2010 (NCT01054014)
Timeline
Indications
Mechanism of action
CSF1R inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC1(C)CC=C(c2nc(C3CC(C)(C)OC(C)(C)C3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1- Mol. weight
- 461.61 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3674570 ↗
- ChEMBLCHEMBL3545319 ↗
Also known as
- jnj-40346527
- jnj-40346527
- jnj-40346527
- jnj-40346527
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04121208 | Phase 1 | Nov 30, 2019 | Janssen Pharmaceutica NV, University of Oxford |
| NCT03557970 | Phase 2 | Nov 30, 2018 | OHSU Knight Cancer Institute |
| NCT01597739 | Phase 2 | Jul 1, 2012 | Johnson and Johnson |
| NCT01572519 | Phase 1 | Jun 1, 2012 | Johnson and Johnson |
| NCT01054014 | Phase 1 | Jan 1, 2010 | Johnson and Johnson |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 3 | 3 | 2 | 2010 |
| Janssen Pharmaceutica NV | For profit | 1 | 0 | 1 | 2019 |
| OHSU Knight Cancer Institute | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of Oxford | Academic/Hospital | 1 | 1 | 1 | 2019 |
4 organizations
Page 1 / 1